This post is sponsored by BioCrossroads and written by its President and CEO, David L. Johnson.
Welcome to Indiana! BioCrossroads is excited to partner with MedCity News to spread the word about Indiana’s life sciences sector.
BioCrossroads’ mission is to grow, advance and invest in Indiana’s life sciences sector. We have raised more than one-quarter billion dollars (in both grant funds and capital investments) for life sciences opportunities, organized four venture capital funds, and launched eight new enterprises that showcase some of our leading life sciences assets. Those enterprises include, for example, the Indiana Health Information Exchange to advance our pioneering work in health information technology, or OrthoWorx to capitalize on our dominance of nearly a third of the global orthopedics industry from the small and picturesque community of Warsaw, Indiana. Collaborating with industry, academia and government partners, we are busy writing a 21st-century chapter for our continuing story of more than a century of life sciences start-ups and strengths.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Indiana is recognized — and more than occasionally envied — for our increasingly clear role as a global center for life sciences innovation. Throughout the state, life sciences represent today a $44 billion industry, with economic clout and worldwide reach that have put Indiana on the map of places that count when it comes to medical technology and biotechnology. This critical sector represents more than 50,000 direct jobs, thousands more in supply and support, and more than 825 companies and growing. In 2010, more than $9.1 billion worth of life sciences products were exported from Indiana, ranking us third highest in the U.S., behind only California and Texas.
Let us know if you’d like to hear more about our story and strategy for BioCrossroads and Indiana’s life sciences industry. We’re always eager to share the good news.
Sincerely,
David L. Johnson
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
President and CEO
BioCrossroads is Indiana's initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region's existing research and corporate strengths while encouraging new business development.
